Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

As part of its single technology appraisal process, the National Institute for Health and Care Excellence invited the manufacturer (Eli Lilly) of baricitinib (BARI; Olumiant(®); a Janus kinase inhibitor that is taken orally) to submit evidence of its clinical and cost effectiveness for the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Shijie, Bermejo, Iñigo, Simpson, Emma, Wong, Ruth, Scott, David L., Young, Adam, Stevenson, Matt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999127/
https://www.ncbi.nlm.nih.gov/pubmed/29502174
http://dx.doi.org/10.1007/s40273-018-0616-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999127/
https://www.ncbi.nlm.nih.gov/pubmed/29502174
http://dx.doi.org/10.1007/s40273-018-0616-7

Ejemplares similares